SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $42.5 million in its fourth quarter.
On a per-share basis, the Salt Lake City-based company said it had a loss of 47 cents. Earnings, adjusted for one-time gains and costs, came to 3 cents per share.
The results met Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was also for earnings of 3 cents per share.
The molecular diagnostic company posted revenue of $210.6 million in the period.
For the year, the company reported a loss of $127.3 million, or $1.41 per share. Revenue was reported as $837.6 million.
For the current quarter ending in March, Myriad expects its results to range from a loss of 8 cents per share to a loss of 4 cents per share.
The company said it expects revenue in the range of $196 million to $204 million for the fiscal first quarter.
Myriad expects full-year earnings in the range of 7 cents to 11 cents per share, with revenue ranging from $840 million to $860 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.